Stereotaxis and Shanghai MicroPort EP Medtech Co., Ltd. announced on December 9, 2024, that the Magbot™ Magnetic Navigation Ablation Catheter received regulatory approval from China’s National Medical Products Administration (NMPA). The Magbot™ Catheter is a single-use magnetic saline-irrigated radiofrequency ablation catheter, developed jointly by MicroPort EP and Stereotaxis.
This catheter is designed to work exclusively with Stereotaxis’ robotic systems, including the recently NMPA-approved Genesis RMN, and MicroPort EP’s Columbus™ 3D EP Mapping System. Magbot™ incorporates advanced design features to enhance the efficiency, effectiveness, and safety of robotic magnetic catheter ablation, allowing precise navigation to difficult-to-access heart areas.
The NMPA approval for Magbot™ covers the ablation of drug-resistant persistent atrial fibrillation, atrioventricular nodal reentrant tachycardia, and atrioventricular reentrant tachycardia. MicroPort EP will initiate the commercial launch in China, with Stereotaxis sharing in the proceeds from Magbot™ adoption. This milestone reflects a commitment to improving global cardiovascular care and pioneering innovative technologies in electrophysiology.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.